Migraine drug takes on pancreatic cancer in early trial
NCT ID NCT07475234
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tests whether adding the migraine drug rimegepant to standard chemotherapy can help people with metastatic pancreatic cancer. About 30 adults who have not had prior treatment will receive the combination. Researchers will track how long the cancer stays under control and monitor for side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- rimegepant (a migraine drug) combined with nab-paclitaxel and gemcitabine (standard chemotherapy)
- What this could lead to
- If it works, this could point toward a new first-line treatment option for metastatic pancreatic cancer, potentially slowing disease progression.
- What could go wrong
- This is a very early, small trial (30 people) with no control group. The drug combination may not work better than standard care, and side effects could be significant.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can an immunotherapy cocktail slow pancreatic cancer? a new trial aims to find out.
- Smart drug delivers chemo directly to pancreatic cancer cells
- Engineered T-Cells take aim at Hard-to-Treat pancreatic cancer
- Could a stomach drug help fight pancreatic cancer?
- New hope for tough pancreatic cancer? drug combo targets KRAS mutations
- Experimental vaccine combo takes on tough pancreatic cancer